Abstract
Novel bioactive opioid mimetic agonists containing 2′,6′-dimethyl-l-tyrosine (Dmt) and a pyrazinone ring interact with μ-and δ-opioid receptors. Compound 1 [3-(4′ -Dmt-aminobutyl)-6-(3′-Dmt-aminopropyl)-5-methyl-2(1H)pyrazinone] exhibited high μ-opioid receptor affinity and selectivity (Kiμ = 0.021 nM and Kiδ/Kiμ = 1,519, respectively), and agonist activity on guinea pig ileum (IC50 = 1.7 nM) with weaker δ-bioactivity on mouse vas deferens (IC50 = 25.8 nM). Other compounds (2-4) had μ-opioid receptor affinities and selectivities 2- to 5-fold and 4- to 7-fold less than 1, respectively. Intracerebroventricular administration of 1 in mice exhibited potent naloxone reversible antinociception (65 to 71 times greater than morphine) in both tail-flick (TF) and hot-plate (HP) tests. Distinct opioid antagonists had differential effects on antinociception: naltrindole (δ-antagonist) partially blocked antinociception in the TF, but it was ineffective in the HP test, whereas β-funaltrexamine (irreversible antagonist, μ1/μ2-subtypes) but not naloxonazine (μ1-subtype) inhibited TF test antinociception, yet both blocked antinociception in the HP test. Our data indicated that 1 acted through μ- and δ-opioid receptors to produce spinal antinociception, although primarily through the μ2-receptor subtype; however, the μ1-receptor subtype dominates supraspinally. Subcutaneous and oral administration indicated that 1 crossed gastrointestinal and blood-brain barriers to produce central nervous system-mediated antinociception. Furthermore, daily s.c. dosing of mice with 1 for 1 week developed tolerance in a similar manner to that of morphine in TF and HP tests, implicating that 1 also acts through a similar mechanism analogous to morphine at μ-opioid receptors.
Footnotes
-
DOI: 10.1124/jpet.103.060061.
-
ABBREVIATIONS: Dmt, 2′,6′-dimethyl-l-tyrosine; TF, tail-flick; HP, hot-plate; DPDPE, [d-Pen2,d-Pen5]-enkephalin; DAMGO, [d-Ala2,N-MePhe4,Gly5-ol]-enkephalin; GPI, guinea pig ileum; MVD, mouse vas deferens; NTI, naltrindole hydrochloride; NAZ, naloxonazine; β-FNA, β-funaltrexamine; HPLC, high-performance liquid chromatography; Boc, tert-butyloxycarbonyl; TFL, tail-flick latency; MED, minimum effective dose; AUC, area under the curve; ICI-154,129, N,N-diallyl-Tyr-Gly-ψ-(CH2)-Phe-Leu-OH.
- Received September 15, 2003.
- Accepted December 11, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|